San Antonio Breast Cancer Symposium (SABCS) 2018

Educational Session

Tuesday, December 4th: 5:30 pm - 7:00 pm
Location: Hemisfair Ballroom 2&3 - 3rd Level
Energy balance: The new adjuvant therapy?
Melinda L. Irwin, PhD, MPH

Poster Sessions

Thursday, December 6th: 5:00 pm – 7:00 pm
Tumor Cell and Molecular Biology: Epigenetics
Age-related methylation signals of breast cancer risk in blood
Hofstatter EW, Levine M, Hatzis C, Pusztai L

Friday, December 7th: 7:00 am – 9:00 am
Tumor Cell and Molecular Biology: Novel/Emerging Therapeutic Targets
Targeting loss of isoenzyme diversity as a novel therapeutic strategy in breast cancer
Marczyk M, Pusztai L, Hatzis C.

Tumor Cell and Molecular Biology: Genetics - Germline Changes
Pathway level complementarity of germline and somatic events in breast cancer
Marczyk M, Wali V, Pusztai L, Hatzis C

Prognostic and Predictive Factors: Prognostic Factors - Clinical Testing and Validation
Pre-analytical effects of FFPE extraction methods on targeted and whole transcriptome sequencing assays for endocrine sensitivity in metastatic breast cancer
Marczyk M, Hatzis C

Psychosocial, QOL, and Educational Aspects: Doctor-Patient Communications
Prioritization of patient reported outcomes by women with metastatic breast cancer
Mougalian SS, Presley C, Gross CP
Detection/Diagnosis: Diagnostic Pathology
Analytical validation of an automated digital scoring protocol for Ki67: International multicenter collaboration study
Rimm DL

Friday, December 7\textsuperscript{th}: 5:00 pm – 7:00 pm

Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
\textit{ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer}
Crews CM

Saturday, December 8\textsuperscript{th}: 7:00 am – 9:00 am

Psychosocial, QOL, and Educational Aspects: Other
\textit{Radiation oncologists' views on breast radiation therapy guidelines: Utilizing an online Q&A platform to assess current views on whole breast radiation therapy}
Housri N

Treatment: HER2-Targeted Therapy
\textit{Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer}
Mougalian SS

\textbf{Case Discussion}

Thursday, December 6\textsuperscript{th}: 1:00 pm – 2:00 pm
Location: Stars at Night Ballroom 1&2 - 3rd Level
Lajos Pusztai

\textbf{Spotlight Presentation}
Friday, December 7\textsuperscript{th}
\textit{SHAVE2 trial}
Anees Chagpar